Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Registry of Toxic Effects of Chemical Substances (RTECS)

Phenol, 2,4,6-tribromo-

RTECS #

SN1225000

CAS #

118-79-6

Updated

April 2012

Molecular Weight

330.82

Molecular Formula

C6H3Br3O

Synonyms

2,4,6-Tribromophenol
Bromol
Tribromophenol

Skin and Eye Irritation and References

Route/OrganismDoseEffectReference
eye /rabbit 100 mg mildHPV029 -,-,2002

Reproductive Effects Data and References

Route/OrganismDoseEffectReference
inhalation/rat 100 µg/m3/24H (1-21D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Musculoskeletal system

Reproductive: Effects on newborn: Behavioral
NRTXDN 19,303,1998
inhalation/mouse 0.15 mg/m3 (122D prior to copulation)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on newborn: Other postnatal measures or effects
VCVGK* -,258,1994
inhalation/rat 0.3 mg/m3 (1-20D pregnant)Reproductive: Other effects on female

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Musculoskeletal system
HPV029 -,-,2002
oral/rat 40 mg/kg (1-20D pregnant)Reproductive: Other effects on female

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Musculoskeletal system
HPV029 -,-,2002
oral/rat 10000 mg/kg (6-15D pregnant)Reproductive: Other effects on female

Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on embryo or fetus: Fetal death
HPV029 -,-,2002

Acute Toxicity Data and References

Route/OrganismDoseEffectReference
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 37 µmol/L/24HIn Vitro Toxicity Studies: Cell countingTIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 12.5 µmol/L/24HIn Vitro Toxicity Studies: Cell countingTIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 15 µmol/L/48HIn Vitro Toxicity Studies: Cell countingTIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 4 µmol/L/48HIn Vitro Toxicity Studies: Cell countingTIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 14 µmol/L/72HIn Vitro Toxicity Studies: Cell countingTIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 6.4 µmol/L/72HIn Vitro Toxicity Studies: Cell countingTIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 80 µmol/L/24HIn Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.)TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 24.5 µmol/L/24HIn Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.)TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 80 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 2.1 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 29 µmol/L/48HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 0.5 µmol/L/48HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 20 µmol/L/72HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 2.7 µmol/L/72HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): >200 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 96 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 14 µmol/L/48HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 10.3 µmol/L/48HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 30 µmol/L/72HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 19 µmol/L/72HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): >200 µmol/L/24HIn Vitro Toxicity Studies: Other assaysTIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): >200 µmol/L/24HIn Vitro Toxicity Studies: Other assaysTIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 13 µmol/L/48HIn Vitro Toxicity Studies: Other assaysTIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 0.7 µmol/L/48HIn Vitro Toxicity Studies: Other assaysTIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 7.5 µmol/L/72HIn Vitro Toxicity Studies: Other assaysTIVIEQ 17,635,2003
In Vitro/Human, neuroblastoma Inhibitor Concentration (20 percent kill): 0.4 µmol/L/72HIn Vitro Toxicity Studies: Other assaysTIVIEQ 17,635,2003
inhalation/rat lethal concentration (50 percent kill): >1630 mg/m3/4HOlfaction: Other olfaction effects

Eye: Ptosis
NTIS** OTS0523305
inhalation/rat lethal concentration (50 percent kill): >1630 mg/m3/4HEye: PtosisHPV029 -,-,2002
inhalation/rat lethal concentration (50 percent kill): >200000 mg/m3/1HBehavioral: Somnolence (general depressed activity)

Lung, Thorax, or Respiration: Dyspnea

Gastrointestinal: Changes in structure or function of salivary glands
HPV029 -,-,2002
oral/guinea pig lowest published lethal dose: 3 gm/kgNTIS** OTS0522208
oral/rat lethal dose (50 percent kill): 200 mg/kgVCVGK* -,257,1994
skin/rabbit lethal dose (50 percent kill): >2000 mg/kgNutritional and Gross Metabolic: Weight loss or decreased weight gainHPV029 -,-,2002

Other Multiple Dose Data and References

Route/OrganismDoseEffectReference
inhalation/rat lowest published toxic concentration: 100 mg/m3/6H/3W- intermittentBehavioral: Somnolence (general depressed activity)

Gastrointestinal: Changes in structure or function of salivary glands

Nutritional and Gross Metabolic: Weight loss or decreased weight gain
NTIS** OTS0523305
inhalation/rat lowest published toxic concentration: 100 mg/m3/3W- intermittentNutritional and Gross Metabolic: Weight loss or decreased weight gainHPV029 -,-,2002
inhalation/rat lowest published toxic concentration: 1000 mg/m3/3W- intermittentLiver: Other changes

Kidney, Ureter, and Bladder: Other changes

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
HPV029 -,-,2002
intradermal/guinea pig lowest published toxic dose: 20 mg/kg/3W- intermittentImmunological Including Allergic: Increased immune responseHPV029 -,-,2002
skin/rabbit lowest published toxic dose: 20000 mg/kg/4W- intermittentSkin: After topical application: Corrosive

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
HPV029 -,-,2002

Reviews

OrganizationStandardReference
TOXICOLOGY REVIEWMUREAV 741,32,2012

NIOSH Documentation and Surveillance

OrganizationStandardReference
National Occupational Exposure Survey 1983Hazard Code X4026; Number of Industries 2; Total Number of Facilities 64; Number of Occupations 3; Total Number of Employees Exposed 1427; Total Number of Female Employees Exposed 734

Status in Federal Agencies

OrganizationReference
EPA TSCA 8(a) PRELIMINARY ASSESSMENT INFORMATION, FINAL RULEFEREAC 47,26992,82
EPA TSCA Section 8(b) CHEMICAL INVENTORY
EPA TSCA Section 8(d) unpublished health/safety studies
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
TOP